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Background: Paravalvular aortic regurgitation (PVAR) is associated with a poor clinical outcome after Transcatheter aortic valve 
replacement (TAVR). We evaluated cardiac hemodynamics to understand the natural history and mechanism of PVAR after TAVR with the 
self-expanding CoreValve.
methods: Serial echocardiography studies performed in a multi-center TAVR study that enrolled extreme risk patients (pts) with severe 
aortic stenosis (AS) who underwent TAVR with the self-expanding CoreValve were analyzed by an Echocardiography Core Laboratory. 
Primary measures were the hemodynamic performance of CoreValve over time and the outcome of PVAR over 1 year followup [discharge, 
1,6,12 months]. Secondary measures were the anatomic and functional changes after CoreValve implantation. 
results: CoreValve was implanted in 634 pts (age 83 ± 8 yrs.). There was a marked acute improvement in AV mean pressure gradient 
from 47.81±15.20 mmHg to 9.67±4.44 mmHg, P<.0001, and effective orifice area (EOA) from 0.73± 0.24 cm2 to 1.78± 0.51 cm2, P<.0001 
at discharge. They improved further significantly by 1 month (8.93±4.62 mmHg, P<.0001 and 1.85±0.58 cm2, P = .03, respectively) while 
stroke volume increased. The improvement continued through 1 year follow-up. At discharge, PVAR, was moderate or severe in 9.8% 
which was reduced to 3.9% at 1 year. Of 36 patients with moderate PVAR, 30 (83%) improved at least one grade of PVAR at 1 year [paired 
data]. Oversizing of CoreValve was significantly greater in patients with none- trivial PVAR vs those with at least mild PVAR at discharge 
and/or at 1 year. Only severe PVAR at discharge was associated with overall mortality. There was gradual and significant improvement in 
LV EF, mass index and diastolic filling pressure.
conclusion:  There were continuous improvement (mostly within the first month) in AV hemodynamics and regression of PVAR at 1 
year compared to discharge in severe AS patients who were treated with CoreValve. These changes appear to be due to remodeling or 
continuous expansion of the self-expandable CoreValve with Nitinol frame in combination of adequate oversizing.
